Cornerstone Lung Cancer Drug Achieves 90% Response Rate

Edgen Stock

·Mar 26 2026, 09:36

Share to

Share to

Copy link

Key Takeaways

Cornerstone Pharmaceuticals announced exceptionally positive preliminary data for its tri-specific antibody, CS2009. The drug demonstrated a 90% objective response rate in a key group of lung cancer patients, signaling a potential new standard of care and positioning the company for significant growth.

Exceptional Efficacy: CS2009 achieved a 90% objective response rate (ORR) and a 100% disease control rate (DCR) in first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression.
Favorable Safety: The trial reported a 23% incidence of grade 3 or higher treatment-related adverse events, notably avoiding severe toxicities common in similar combination immunotherapies.
Clear Development Path: Cornerstone plans to initiate global Phase III multi-center clinical trials by the end of 2026, targeting lung, colorectal, and small cell cancers.

CS2009 Achieves 90% Response Rate in First-Line Lung Cancer

Cornerstone Pharmaceuticals (02616.HK) released preliminary Phase I/II clinical data showing its investigational antibody, CS2009, produced a 90% objective response rate (ORR) and a 100% disease control rate (DCR) in first-line non-small cell lung cancer (NSCLC) patients. The positive results were observed in patients with a PD-L1 tumor proportion score of 50% or higher, a significant sub-group in lung cancer treatment. The tri-specific antibody, which targets PD-1, VEGF, and CTLA-4, also demonstrated a 25% ORR in heavily pre-treated second-line NSCLC patients who had previously undergone immunotherapy, indicating its potential efficacy in difficult-to-treat populations.

Favorable Safety Profile Paves Way for 2026 Phase III Trials

The treatment's safety profile appears to be a key advantage. The study, which enrolled 113 patients with advanced solid tumors as of mid-March, recorded a 23% incidence of grade 3 or higher treatment-related adverse events. Crucially, the trial did not find the severe toxicities often associated with CTLA-4 and PD-(L)1 combination therapies, suggesting a more manageable side-effect profile. Bolstered by these results, Cornerstone Pharmaceuticals intends to launch the first global Phase III multi-center clinical trials for CS2009 by the end of 2026. The company plans to investigate the drug for NSCLC, colorectal cancer, and small cell lung cancer, with more detailed data expected at major oncology conferences in 2026.